Welcome to the IMPACCT Real World Evidence Summit West
Welcome to the IMPACCT Real World Evidence Summit West, your one stop shop for cutting-edge case studies and strategic insights uniting clinical, market access, regulatory, and commercial teams to advance RWE utility across the drug development life cycle. This event brings together 70+ RWE experts across pharma and biotech companies including Genentech, Takeda, NICE, Roche, Ultragenyx, Gilead Sciences, and more to bullet-proof data quality, enhance RWE generation, and streamline cross-functional collaboration.
4 reasons making this a must-attend event:
- Uncover practical strategies to integrate AI, genomics, and digital health tools into real-world evidence generation improving the speed, scale, and relevance of insights across the product lifecycle
- Learn how to enhance evidence generation in rare and complex disease areas by embedding patient voice, real-world endpoints, and collaborative data strategies to overcome challenges in data availability and diversity
- Take away proven approaches to improve digital and decentralized data quality, with actionable frameworks for tackling attribution issues, engagement variability, and trust in new data sources
- Gain tools to translate complex RWE and HEOR outputs into clear, decision-ready insights, enabling stronger alignment across clinical, commercial, regulatory, and field-facing teams.
Explore the Full Event Guide
With 14+ world-class speakers and 3 days of the hottest content, the IMPACCT Real World Evidence Summit West agenda will showcase the latest case studies and best practice for leveraging RWE to advance decision making in clinical research, regulatory submissions, payer negotiations & market access.
Discover the Full Event Guide below!
• Uncover what constitutes ‘fit-for-purpose’ evidence from a payer and HTA body perspective.
• Enhance the predictive value of real-world studies through deeper biological context and mechanistic understanding.
• Balancing nuance and clarity while ensuring analytical complexity and audience accessibility is preserved.
• Takeaways from industry strategies to move from reactive fixes to proactive data governance and quality-by-design approaches.
Attending Companies Include
